• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生物标志物能否指导溶瘤病毒免疫疗法？

Can Biomarkers Guide Oncolytic Virus Immunotherapy?

作者信息

Kaufman Howard L

机构信息

Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Cancer Res. 2021 Jun 15;27(12):3278-3279. doi: 10.1158/1078-0432.CCR-21-0660. Epub 2021 Apr 13.

DOI:10.1158/1078-0432.CCR-21-0660
PMID:33849964
Abstract

Defects in tumor cell IFNγ signaling is associated with resistance to immune checkpoint inhibitors. Recently, these defects were found to confer increased sensitivity to oncolytic virus infection. Differential expression of innate sensing elements in tumor cells may serve as predictive biomarkers of oncolytic virus immunotherapy in patients with cancer..

摘要

肿瘤细胞干扰素γ信号通路的缺陷与对免疫检查点抑制剂的耐药性有关。最近，发现这些缺陷会使肿瘤细胞对溶瘤病毒感染的敏感性增加。肿瘤细胞中固有传感元件的差异表达可能作为癌症患者溶瘤病毒免疫治疗的预测生物标志物。

相似文献

1
Can Biomarkers Guide Oncolytic Virus Immunotherapy?生物标志物能否指导溶瘤病毒免疫疗法？
Clin Cancer Res. 2021 Jun 15;27(12):3278-3279. doi: 10.1158/1078-0432.CCR-21-0660. Epub 2021 Apr 13.
2
Development of oncolytic virotherapy: from genetic modification to combination therapy.溶瘤病毒治疗的发展：从基因修饰到联合治疗。
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
3
Integrating oncolytic viruses in combination cancer immunotherapy.将溶瘤病毒整合到联合癌症免疫疗法中。
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
4
Oncolytic polio virotherapy of cancer.肿瘤溶瘤脊髓灰质炎病毒治疗癌症。
Cancer. 2014 Nov 1;120(21):3277-86. doi: 10.1002/cncr.28862. Epub 2014 Jun 17.
5
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.干扰素通路缺陷作为溶瘤病毒敏感性的潜在生物标志物。
Rev Med Virol. 2018 Nov;28(6):e2008. doi: 10.1002/rmv.2008. Epub 2018 Sep 13.
6
Oncolytic Immunotherapy.溶瘤免疫疗法
Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.
7
From virotherapy to oncolytic immunotherapy: where are we now?从病毒疗法到溶瘤免疫疗法：我们现在在哪里？
Curr Opin Virol. 2015 Aug;13:93-100. doi: 10.1016/j.coviro.2015.06.005. Epub 2015 Jun 26.
8
Oncolytic virotherapy: Challenges and solutions.溶瘤病毒治疗学：挑战与对策。
Curr Probl Cancer. 2021 Feb;45(1):100639. doi: 10.1016/j.currproblcancer.2020.100639. Epub 2020 Aug 15.
9
Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.区分代谢重编程在溶瘤病毒免疫治疗中的利弊。
Int J Cancer. 2022 Nov 15;151(10):1654-1662. doi: 10.1002/ijc.34139. Epub 2022 Jun 13.
10
Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).一种新型溶瘤痘苗病毒的抗肿瘤疗效增强，该病毒编码针对 T 细胞免疫球蛋白和 ITIM 结构域（TIGIT）的完全单克隆抗体。
EBioMedicine. 2021 Feb;64:103240. doi: 10.1016/j.ebiom.2021.103240. Epub 2021 Feb 10.

引用本文的文献

1
VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity.VAX014激活肿瘤内在的STING和RIG-I以促进抗肿瘤免疫的发展。
Mol Cancer Ther. 2025 Apr 2;24(4):587-604. doi: 10.1158/1535-7163.MCT-24-0509.
2
Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses.优化胰腺癌治疗：免疫刺激溶瘤病毒的前景。
Int J Mol Sci. 2024 Sep 13;25(18):9912. doi: 10.3390/ijms25189912.
3
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments.
增强癌症治疗效果：溶瘤病毒疗法与多种治疗方法的整合
Cancer Cell Int. 2024 Jul 11;24(1):242. doi: 10.1186/s12935-024-03424-z.
4
New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.乳腺癌治疗的新希望：溶瘤病毒治疗的展望。
Front Immunol. 2024 Mar 21;15:1375433. doi: 10.3389/fimmu.2024.1375433. eCollection 2024.
5
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.肿瘤溶瘤病毒治疗癌症：挑战与优化前景。
Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023.
6
Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.新辅助全身溶瘤性水疱性口炎病毒是安全的，并且可能提高自然发生骨肉瘤的犬的长期生存率。
Mol Ther Oncolytics. 2023 Oct 14;31:100736. doi: 10.1016/j.omto.2023.100736. eCollection 2023 Dec 19.
7
Oncolytic virotherapies for pediatric tumors.肿瘤溶瘤病毒疗法治疗儿科肿瘤。
Expert Opin Biol Ther. 2023 Jul-Dec;23(10):987-1003. doi: 10.1080/14712598.2023.2245326. Epub 2023 Oct 5.
8
Therapy with oncolytic viruses: progress and challenges.溶瘤病毒疗法：进展与挑战。
Nat Rev Clin Oncol. 2023 Mar;20(3):160-177. doi: 10.1038/s41571-022-00719-w. Epub 2023 Jan 11.
9
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.通过合理组合溶瘤病毒与靶向关键信号通路的调节剂来改善癌症免疫疗法。
Mol Cancer. 2022 Oct 12;21(1):196. doi: 10.1186/s12943-022-01664-z.
10
How cancer cells make and respond to interferon-I.癌细胞如何产生和应对干扰素-I。
Trends Cancer. 2023 Jan;9(1):83-92. doi: 10.1016/j.trecan.2022.09.003. Epub 2022 Oct 8.